Abstract
Rabies is a zoonose affecting wild and domestic animals and transmitted to humans through bites or scratches, causing over 60,000 human deaths, annually. The disease results from the transmission of a neurotropic virus leading to invariably deadly encephalitis. The post-exposure prophylaxis consists of careful washing and disinfection of the wound, antibiotherapy and tetanus prophylaxis when needed. Furthermore, rabies vaccine and rabies immunoglobulin [RIG] administration should be applied according to the type of wound, and the animal involved, according to the WHO protocols that are regularly updated. Unfortunately it is sometimes difficult to obtain RIG in some countries due to their high cost, leading to suboptimal treatment and possible death. Also, observance can be weak, due to the number of repeated visits required with protocols [up to five visits over 28 days]. These limitations justify research on new vaccines which were not conclusive at the moment. New RIGs are under development, including a monoclonal antibody cocktail which is more promising in a near future. Finally, vaccination protocols are in the way of being shortened in given conditions. Further studies are needed to validate these new practices.
Keywords: Humans, post exposure prophylaxis, rabies immunoglobulin, rabies, recommendations, vaccines.
Infectious Disorders - Drug Targets
Title:Current Perspectives on Rabies Postexposure Prophylaxis
Volume: 15 Issue: 1
Author(s): Agathe Blaise and Philippe Gautret
Affiliation:
Keywords: Humans, post exposure prophylaxis, rabies immunoglobulin, rabies, recommendations, vaccines.
Abstract: Rabies is a zoonose affecting wild and domestic animals and transmitted to humans through bites or scratches, causing over 60,000 human deaths, annually. The disease results from the transmission of a neurotropic virus leading to invariably deadly encephalitis. The post-exposure prophylaxis consists of careful washing and disinfection of the wound, antibiotherapy and tetanus prophylaxis when needed. Furthermore, rabies vaccine and rabies immunoglobulin [RIG] administration should be applied according to the type of wound, and the animal involved, according to the WHO protocols that are regularly updated. Unfortunately it is sometimes difficult to obtain RIG in some countries due to their high cost, leading to suboptimal treatment and possible death. Also, observance can be weak, due to the number of repeated visits required with protocols [up to five visits over 28 days]. These limitations justify research on new vaccines which were not conclusive at the moment. New RIGs are under development, including a monoclonal antibody cocktail which is more promising in a near future. Finally, vaccination protocols are in the way of being shortened in given conditions. Further studies are needed to validate these new practices.
Export Options
About this article
Cite this article as:
Blaise Agathe and Gautret Philippe, Current Perspectives on Rabies Postexposure Prophylaxis, Infectious Disorders - Drug Targets 2015; 15 (1) . https://dx.doi.org/10.2174/1871526515666150320161630
DOI https://dx.doi.org/10.2174/1871526515666150320161630 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prediction of Potential Targets of an Emerging Zoonotic Paramyxovirus: An Integrated Bioinformatics Analysis
Current Pharmacogenomics and Personalized Medicine Modulation of γ<sub>2</sub>-MSH Hepatoprotection by Antisense Peptides and Melanocortin Subtype 3 and 4 Receptor Antagonists
Medicinal Chemistry Status Epilepticus: An Overview
Current Drug Metabolism Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Peptide Based Viral Detection Systems for Effective Diagnosis of Common Viral Infections in India
Current Protein & Peptide Science A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Amygdalar Atrophy in Early Alzheimer’s Disease
Current Alzheimer Research Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology Role of CD14 in Host Response to Infection
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Nicotine and Nicotinic Receptor Involvement in Neuropsychiatric Disorders
Current Topics in Medicinal Chemistry T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Short Review: Green Trends in Insect Control Edited by O Lopez and J. G. Fernandez- Bolanos
Current Green Chemistry Legumes: A Healthy and Ecological Source of Flavonoids
Current Nutrition & Food Science A179L, a New Viral Bcl2 Homolog Targeting Beclin 1 Autophagy Related Protein
Current Molecular Medicine Targeting Protozoan Parasite Metabolism: Glycolytic Enzymes in the Therapeutic Crosshairs
Current Medicinal Chemistry Animal Models Used for the Evaluation of Antiretroviral Therapies
Current HIV Research Disease Modifying Therapeutic Strategies in Alzheimers Disease Targeting the Amyloid Cascade
Current Neuropharmacology The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology